A randomized, open-label, phase 3 study of nivolumab in combination with ipilimumab vs extreme regimen (cetuximab plus cisplatin/carboplatin plus fluorouracil) as first-line therapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck-CheckMate 651

被引：13

作者：

Argiris, A. ^{[1
]}

Gillison, M. ^{[2
]}

Ferris, R. L. ^{[3
]}

Harrington, K. ^{[4
]}

Sanchez, T. K. ^{[5
]}

Baudelet, C. ^{[6
]}

Geese, W. J. ^{[7
]}

Shaw, J. ^{[8
,9
]}

Haddad, R. ^{[10
]}

机构：

[1] Hygeia Hosp, Med Oncol, Athens, Greece

[2] Ohio State Univ, Coll Med, Internal Med, Columbus, OH 43210 USA

[3] Univ Pittsburgh, Inst Eye & Ear, Dept Otolaryngol, Div Head & Neck Surg, Pittsburgh, PA 15213 USA

[4] Inst Canc Res, Div Radiotherapy & Imaging, London, England

[5] Bristol Myers Squibb, Oncol, Global Clin Res, Princeton, NJ USA

[6] Bristol Myers Squibb, Biostat, Princeton, NJ USA

[7] Bristol Myers Squibb, Oncol, Lawrence Township, NJ USA

[8] Bristol Myers Squibb, Clin Outcomes Assessment, Princeton, NJ USA

[9] Bristol Myers Squibb, I O LCM Worldwide Hlth Econ & Outcomes Res, Princeton, NJ USA

[10] Dana Farber Harvard Canc Ctr, Head & Neck Oncol Program, Boston, MA USA

来源：

关键词：

D O I：

10.1093/annonc/mdw376.68

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1016TiP

引用

页数：1